• People
  • Practices
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Podcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Search
  • Biography
  • Education
Profile Picture

Robert Phillips

Robert
Phillips

Partner

CONTACT INFO

rphillips@gibsondunn.com

TEL:+1 415.393.8239

FAX:+1 415.374.8486

San Francisco

555 Mission Street, Suite 3000, San Francisco, CA 94105-0921 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

Life Sciences Capital Markets Emerging Companies Securities Regulation and Corporate Governance

BIOGRAPHY

Robert Phillips is a corporate partner in the San Francisco office of Gibson, Dunn & Crutcher, where his practice focuses on advising life sciences, medical device and technology companies.  Rob has extensive experience advising public and private companies on general corporate issues, including corporate finance, securities laws compliance, corporate governance, debt exchanges and complex restructurings and M&A.  In particular, he focuses on advising US and non-US issuers and investment banks in capital markets offerings, including initial public offerings, follow-ons, convertible debt and high yield debt offerings.

Notable representations across industries include:

 Life Sciences and Medical Device

  • 89Bio, in its initial public offering and follow on offering (underwriter-side representation)
  • AcelRX Pharmaceuticals, in follow-on offerings and public company representation
  • ARMO Biosciences, in its initial public offering (underwriter-side representation)
  • ASLAN Pharmaceuticals, in its US IPO and public company representation
  • Avalanche Biotechnologies (now Adverum), in its initial public offering
  • BioMarin, in follow-on equity and convertible debt public offerings
  • Five Prime Therapeutics, in a follow-on offering
  • Global Blood Therapeutics, in a follow-on offering (underwriter-side representation)
  • Harpoon Therapeutics, in its initial public offering and public company representation
  • InterMune, in convertible debt offerings and debt exchanges
  • Jazz Pharmaceuticals, in a follow-on offering, convertible debt offerings and public company representation
  • Legend Biotech Corporation, in its initial public offering
  • Kezar Life Sciences, in its initial public offering, follow-on offering and public company representation
  • Ovid Therapeutics, in its initial public offering, follow-on offerings and public company representation
  • Prothena, in its spin-off from Elan Pharmaceuticals, follow-on equity offerings and public company representation
  • Sangamo Therapeutics, in follow-on offerings and public company representation
  • Sientra, in public company representation and securities laws compliance
  • Syndax Pharmaceuticals, in aa follow-on offering
  • Taiwan Liposome Company, in its US initial public offering and public company representation
  • Threshold Pharmaceuticals, in public company representation, financings and reverse merger with Molecular Templates
  • Vaxcyte, in its initial public offering and general corporate representation
  • XenoPort, in public company representation and financings

Technology

  • Advanced Micro Devices, in numerous equity, high yield and convertible debt financings and the formation of a joint venture with Fujitsu Limited to create Spansion (now part of Broadcom)
  • Aquantia, in its initial public offering
  • Avago (now Broadcom), in its initial public offering and follow-on offerings
  • eASIC Corporation, in general company representation, late-stage equity financings and sale to Intel
  • Ellie Mae, in its initial public offering, follow-on offering, strategic acquisitions and public company representation
  • Handshake (joinhandshake.com), in general corporate representation and equity financings
  • Oportun, in its initial public offering, general corporate representation and financings
  • RealD, in public company representation and securities laws compliance
  • ShotSpotter, in its initial public offering, a follow-on offering and public company representation
  • Spansion, in its initial public offering, high yield and convertible debt financings, follow-on offerings, fab sale and public company representation

Aviation

  • Virgin America, in debt and equity restructurings with private equity owners and preparation for its initial public offering
  • Spirit Airlines, in an equity restructuring with private equity owners and in its initial public offering, follow-on offerings and public company representation

Retail

  • Blue Nile, in public company representation and securities laws compliance
  • Charlotte Russe Stores, in corporate advice and restructuring
  • Golfsmith, in acquisition of retail chain of golf stores

Prior to joining Gibson Dunn, Rob was a partner in the San Francisco office and Hong Kong office of Cooley LLP, and before that a partner in the Silicon Valley and San Francisco offices of Latham & Watkins LLP, where he began his legal career.

EDUCATION

Georgetown University - 1999 Juris Doctor

Georgetown University - 1994 B.S. in Foreign Service

ADMISSIONS

California Bar

  • Sitemap
  • Client Extranet
  • Terms of Use and Legal Notices
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2023 Gibson, Dunn & Crutcher LLP.  All rights reserved.  For contact and other information, please visit us at gibsondunn.com.
Top
Gibson Dunn uses cookies which are essential for our website to function. With your consent, we and third parties may also use non-essential cookies to collect information about your browsing activities, and improve the content, functionality and performance of our website. By clicking “Accept All”, you consent to the use of all cookies on our website as set out in our Cookie Notice. You can reject all non-essential cookies by clicking “Reject All”. Choose "Manage Cookies" to view and customize your cookie settings.
Manage CookiesACCEPT ALLREJECT ALL
Manage consent

Your Privacy Choices / Cookies

This website uses cookies – small text files stored on your device, when you visit a website - including third party cookies to collect information about your browsing activities and improve the content, functionality and performance of our website. Out of these cookies, the cookies that are categorized as Necessary Cookies are stored on your browser as they are essential for the operation of the website. You may accept all cookies, or reject all cookies other than Necessary Cookies.  If you visit us from a different device or browser, or clear cookies, then you may need to return to this screen to re-select your preferences.   Note that rejecting some of these cookies may have an effect on your browsing experience. Please note that if you do not make a selection below, only necessary cookies will be set.

You can learn more about our processing of your personal data by visiting our Privacy Policy.
Necessary
Always Enabled
Necessary cookies are essential for our website to function and cannot be switched off in our systems. They are usually set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. Without these cookies, our website will not operate properly.   Cookie Details
Analytics
These cookies are used to collect information on how you use our website, including information about the pages you visited, how long you visited and if you experienced any errors. We use this information to help us improve the quality of our website and monitor the level of activity on our website. They may be set by third parties whose services have been added to our pages. Cookie Details
Save & Accept